Background: The use of targeted therapies has recently increased. Pharmacogenetic tests are a useful tool to guide patient treatment and to test a response before administering medicines. Pharmacogenetic tests can predict potential drug resistance and may be used for determining genotype-based drug dosage. However, their cost-effectiveness as a diagnostic tool is often debatable. In Germany, 47 active ingredients are currently approved. A prior predictive test is required for 39 of these and is recommended for eight. The objective of this study was to review the cost-effectiveness (CE) of pharmacogenetic test-guided drug therapy and compare the application of drugs with and without prior genetic testing. Methods: A systematic literature review was conducted to identify the CE and cost-utility of genetic tests. Studies from January 2000 until November 2015 were searched in 16 databases including Medline, Embase, and Cochrane. A quality assessment of the full-text publications was performed using the validated Quality of Health Economic Studies (QHES) instrument. Results: In the majority of the included studies, the pharmacogenetic test-guided therapy represents a cost-effective/cost-saving treatment option. Only seven studies lacked a clear statement of CE or cost-savings, because of uncertainty, restriction to specific patient populations, or assumptions for comparative therapy. Moreover, the high quality of the available evidence was evaluated. Conclusion: Pharmacogenetic testing constitutes an opportunity to improve the CE of pharmacotherapy. The CE of targeted therapies depends on various factors including costs, prevalence of biomarkers, and test sensitivity and specificity. To guarantee the CE comparability of stratified drug therapies, national and international standards for Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/30E4 F060671BEE90.
INTRODUCTION
Adverse drug reactions (ADRs) are often responsible of morbidity and mortality [1] . In the USA, it has been estimated that 106,000
deaths per year are caused by ADRs [2] . In Germany, the incidence of ADR-induced hospitalizations amounts to approximately 3.25% of overall hospitalizations, and the overall ADR treatment costs sum to €434 million per year [3] . The field of pharmacogenomics or pharmacogenetics (PG), these terms are sometimes used interchangeably [4, 5] , may be a solution to reduce ADRs [6] . PG constitutes a core area of personalized medicine. The growing knowledge of genetics/ genomics, and particularly the increasing understanding of the genotype-phenotype interaction, forms the basis for this personalized approach. The progress in genetic technology, characterized by faster and cheaper analytical tools, is an essential driver for personalized interventions.
Genetic analyses are the central tools in the new area of personalized medicine (often also termed stratified medicine) [7, 8] . Stratified medicine aims at classifying patients into subgroups according to genetically determined features [9] . For example, patients may be divided into groups based on the known influence of genetic parameters on drug dosage and side effects [10] . Therefore, PG uses information about a person's genetic makeup to choose the best drug as well as the medication dosage for a particular patient [11] . The concept of stratified medicine also includes screening, preventive, or therapeutic measures for a specific subgroup of a patient population [12] .
Pharmacogenetic tests (PTs) can be used to characterize individual patient features at the molecular, genetic, and cellular levels [13, 14] . PT primarily focuses on identifying specific biomarkers or genetic mutations. Generally, biomarkers can provide information for diagnostic, prognostic, and predictive purposes.
In a diagnostic context (especially in an oncologic setting), biomarkers are used to identify a disease or the stage of the disease [15] . The assessment of a patient's overall outcome (e.g., the probability of cancer recurrence after standard treatments) can be provided by prognostic biomarkers [16] .
Furthermore, in a predictive context, biomarkers are used as an efficacy test before drug administration. This test serves the purpose of assessing the likelihood of a positive response after a potential treatment. In this context, predictive biomarkers can help to optimize drug selection, dose, and treatment duration as well as prevent ADRs [17] .
The presence of genetic mutations or deletions can also be used for predictive purposes. Several studies have demonstrated that previously identified genetic mutations, such as those on the epidermal growth factor receptor (EGFR), Kirsten RAS (KRAS), and the breast cancer susceptibility gene I and II (BRCA I, BRCA II), predict resistance to treatment [18, 19] . For example, an identified EGFR gene mutation or an increased EGFR gene copy number is associated with a positive response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC) [20] . On the other hand, a KRAS mutation is an important predictor for resistance to an EGFR-TKI therapy [21] . Moreover, gene mutations can also provide information for optimal drug dosage. For instance, the dosage of azathioprine (AZA) is based on the thiopurine-methyltransferase (TMPT) genotype or activity. Patients with no TMPT activity (TMPT deficient) receive no or a reduced dose of AZA, whereas the dosage of AZA administered in patients with an active TMPT differs [12, 22] .
The outdated concept of ''one size fits all'' should be replaced by stratification and move towards a patient-oriented drug treatment [23] . However, this concept is equally connected to hopes and concerns. Potential advantages of target therapies include increasing clinical effectiveness, e.g., by improving survival [24] , and improving patient safety [25] . On the other hand, there are concerns regarding the increased costs of diagnostic tests [26] . However, in recent years, an increasing number of pharmacogenomics applications have been observed [27] . Currently, 47 drugs for pharmacogenetic therapy are approved in Germany. A genetic diagnostic test prior to drug administration is required for 39 of these drugs and recommended for eight [28] . An overview of pharmacogenetic therapies is provided in supplementary file 1. Additionally, a search was conducted by hand.
Assessment of titles and abstracts was performed independently by two researchers.
Only original studies published in full text were included. Full papers were assessed by two researchers, and disagreements were resolved through discussion. Figure 1 summarizes the search process. To ensure comparability, the results were converted to US dollars at the exchange rate of the year of publication [29, 30] .
The published 100-point Quality of Health Economic Studies (QHES) instrument was used to evaluate the quality of the included studies ( Table 2 ) [31] . The QHES evaluation was also conducted by two independent researches, and the disagreements were resolved through discussion. Was there a statement disclosing the source of funding for the study? 3
Total points
This evaluation consists of 16 items, each providing a score between one and nine. The overall evaluation, after summing the scores of each item, identified the quality of an article, which was categorized into four groups ( Table 3 ).
The evaluation of the article quality was also conducted by two independent experts. This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
The database search identified 1535 records.
After removing 175 duplicates, the title and abstract of the remaining 1360 records were screened. Subsequently, 1238 records were excluded as they did not cover the objective of the study. The remaining 122 records were assessed for eligibility, and inclusion criteria were fulfilled by 27 studies, which were included in the final assessment ( Fig. 1 ).
All studies are characterized by a variety of elements, such as country, perspective, treatment line, active ingredient, treatment strategy, biomarkers, consideration of test costs, consideration of sensitivity, and specificity of the test and funding source. A detailed overview is provided in supplementary material 2.
Quality Assessment (QHES)
The results of the quality assessment using the QHES instrument are presented in Table 4 . An average value of 85.81 was calculated. Three studies [46, 47, 56] were assessed to have a fair quality, while all others achieved a high quality score. The objective of all studies was represented in a clear manner (QHES item 1), but seven did not state the perspective of the study (QHES item 2) [22, 33, 37, 40, 45, 53, 56] .
In three studies, data were not extracted from the best available source (QHES item 3) [32, 48, 49] . Six studies used data from a subgroup analysis (QHES item 4) [32, 36, 37, 42, 52, 53] . The majority of studies, with the exception of one, handled uncertainties properly (QHES item 5) [56] . All studies, with the exception of five, performed an incremental analysis for costs and outcomes between the alternatives (QHES item 6) [38, 39, 47, 51, 56] . Detailed information for the methodology of data extraction was not reported in four studies (QHES item 7) [37, 46, 47, 56] . The majority of studies fulfilled the criteria of QHES items 8 and 9.
Only four studies did not choose the appropriate time horizon or did not discount benefits and costs beyond 1 year (QHES item 8) [43, 46, 51, 55] . Furthermore, four studies failed to measure the costs appropriately or to describe methods for estimations of quantities and unit costs clearly (QHES item 9) [41, 46, 47, 56] . All studies clearly stated the primary outcome (QHES item 10). All studies, except for three, stated valid health outcomes or gave a justification for the measurement used if other more valid and reliable measures were not available (QHES item 11) [12, 47, 48] . In most of the studies, the economic model, methods, and analyses were displayed transparently, except in four (QHES item 12) [22, 39, 46, 52] .
All studies gave a justification for the choice of limitations or assumptions (QHES item 13). The authors of seven studies discussed explicitly the direction and the magnitude of the potential Behl et al. [33] x
Blank et al. [34] x
Blank et al. [35] x
Carlson et al. [36] x
Dong et al. [37] x -x x x x -x x x x x x -x x 85
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Marra et al. [47] x
Nieves Calatrava et al. [48] x
Oh et al. [49] x
Plumpton et al. [50] x x x -x x x x x x x x x -x x 93
Priest et al. [51] x
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Winter et al. [56] x determined. In the test strategy, patients with an EGFR mutation received gefitinib followed by chemotherapy as second-line therapy.
Patients without EGFR mutation received chemotherapy with subsequent BSC.
Main Results of This Systematic Review
In this systematic review, six main results were obtained: 1. In the majority of studies, a PT-guided administration of an active ingredient was found to be cost-effective or leads to cost savings. 
DISCUSSION
This comprehensive review analyzed the CE of PT-guided therapies. For this propose we included only studies that compared the CE of the administration of an active ingredient with or without a prior predictive test. PTs serve to determine the effectiveness of active ingredients, to take a therapeutic decision, and ultimately to optimize patient benefit by avoiding ADRs. Preventing ADRs leads to an increase in drug safety and is therefore the central argument for the application of PTs [57, 58] . However, the usefulness of such pharmacogenetic tools depends on their CE.
CE analyses are essential for reimbursement decisions of new technologies as well as pricing by decision-makers. This review investigated whether PTs contribute to an efficient therapy management.
An average value of 85.81 for all 27 assessed studies was calculated. The evaluation through the QHES instrument is a quality assessment regarding the methodology of the studies. This evaluation considered the specific stratified medicine inadequate. Important criteria in the assessment of PTs are the prevalence of biomarkers, sensitivity, and specificity of the test, as well testing costs.
Generally, innovations are used if they have a significant influence on the outcomes (e.g., on the survival or on the improvement in the quality of life). As a result of the limited healthcare budget, it is essential to assess the additional benefits of the innovation in comparison with previous standards. Therefore, CE analyses are necessary and were used for reimbursement decisions. The CE of a medical intervention depends on whether it will be able to provide benefits at a reasonable cost. CE analyses estimate the ICER of interventions. ICER is an analytical tool of the CE analysis (CEA), which compares the differences in cost of two treatments based on their different outcomes (e.g., new treatment vs. previous treatment). Threshold values vary from country to country. For example, a threshold of US$50,000 is stated as cost-effective in the USA [59] . An intervention with an ICER of less than US$50,000 per additional QALY is classified as cost-effective. The CE depends on several factors. In this comprehensive review some divergent features in the study design, which influenced the CE, were identified.
Perspective of the study The CE of a study depends, among other things, on the chosen perspective (e.g., healthcare system, society) [60] . The missing consideration of indirect cost allows no final assessment and comprehensive interpretation. Ideally, the cost should be collected from a societal perspective. However, for this purpose, the required costs are difficult to quantify (e.g., loss of wages) [61] . to an increased degree of stratification. Fundamentally, a lower biomarker prevalence leads to a lower CE of the PT [63] . According to the lower likelihood to identify a responder, the overall benefit is low. Homogenous groups enable an increase in test validity or the likelihood to identify a responder, as well as the examination of biomarker prevalence values by sensitivity analysis. CEA. RCTs are regarded as the gold standard of data collection [64, 65] . The main problems in this context are low funding, low interest in clinical trials (except studies for approved medications), small patient populations, as well as lack of valid discoveries [66] . It is difficult to conduct an RCT for pharmacogenetic applications. The anticipated differences in treatment effectiveness accompanying the test strategies and the need to generate significant outcomes in patients with a similar genotype require large group sizes [67] .
Costs of testing procedures
Oncology is the most frequently discussed disease area for CEA. This indication area is characterized by the high toxicity of chemotherapeutic agents as well as poor clinical outcomes [68, 69] . This raises the potential to be one of the largest and most attractive fields for pharmacogenomics application. Oncology is particular well suited to show CE, because it is an area with a large number of affected patients and with expensive cancer-associated outcomes (chronic pain, ADRs, death). Minor improvements of outcomes affect the CE, because expensive outcomes such as long hospital stays can be prevented.
There are some economic, clinical, and practical challenges in connection with the development and the application of PTs.
Research
and development of pharmacogenetic applications is characterized by some regulatory challenges [70, 71] and high costs to prove clinical benefits [72] . There is a disincentive for pharmaceutical companies to invest in companion diagnostics [73, 74] : an investment into a market without free pricing is a risk for pharmaceutical companies. Genetic analyses (subgroup analysis) divide the market and reduce the total turnover. In countries without the possibility of dynamic pricing or changes in price according to subgroups or indications, the different value of PTs for the specific subgroups is appropriate. A general problem of personalized medicine is the development of drugs for small patient groups but with the same costs of the research and development needed for the development of drugs for larger groups [75] . The danger of low total turnover by small user groups hinders further research and development in the field of targeted therapies. Therefore, in areas with larger market segmentations, pharmacogenetic research should be financed by public resources [76] . Moreover, payers link pharmacogenetic applications with concerns. PTs as well as proteomic tests seem to be more expensive than conventional diagnostic and prognostic tools [77] . Actually, only a few pharmacogenetic examinations were financed within the uniform value scale, on the basis of pricing of ambulant services (EBM). Performing a PT for eight of 47 active ingredients is not compulsory. For 10 of these 47 active ingredients CEA were conducted. The insufficient basis for a conclusion can be used as a reason for the restrained reimbursement for PTs. Furthermore, the clinical benefit of an intervention (e.g., CE, net benefit) is an essential prerequisite for PT application.
However, because of the lack of evidence for the correlation between the influence of a PT on the clinical outcome [78] , it is difficult to prove the benefit. No test can perfectly predict whether a patient will respond positively to a particular treatment. Various factors influence the therapeutic outcome. Generally, ADRs often occur immediately after treatment [79] . Thus, the outcomes (e.g., cost per avoided ADR) can be quickly and easily observed [61] , especially in oncological studies. Moreover, the effects also depend on monitoring ADR quality.
Some practical challenges are connected with the routine use of PT. The partly missing reimbursement [27, 80] , the lack of clinical guidelines [81] , and the processing time associated with treatment delays [82] preclude their widespread application. Furthermore, the use of PT essentially depends on its acceptance by physicians [83] . The restrained use of PT is the result of the missing clinical validation for the clinical application as well of the missing practical and standardized guidelines [84] . There are also ethical concerns regarding the use of PT. Patients were excluded from target therapies as a result of the test results. The insufficient sensitivity and specificity of PTs may lead to a wrong stratification and therefore to the lack of an effective treatment.
The costs of the tests and which savings could be achieved through the use of predictive tests must be known. If there are higher savings, it is economically sensible to conduct a PT. In modelling the CE of PT, important factors such as the sensitivity and specificity of these tests, degree of gene penetrance, association between genotype and clinical outcome, genotype prevalence in the population, likelihood for ADR, and survival according to the genotype and the treatment strategy should be considered.
The quality assessment through the QHES may be subjective and may represent a major limitation of this study. The assessment of study aspects is easy to determine. In contrast, aspects which aim to evaluate the adequacy are characterized by variances. Therefore, two researchers performed the assessment independently to minimize this subjectivity of the QHES instrument.
National and international standards for the assessment of PT should be defined and implemented to improve the quality of the study. Uncertainties may be decreased by more accurate estimations of effectiveness and costs [85] . Furthermore, an independent financing system (e.g., public financing) could enhance the credibility of the results. Such studies are focusing not solely on effectiveness but also on efficiency.
CONCLUSION
The application of personalized therapies is partly associated with high economic costs.
This review has demonstrated that, in the majority of the studies included here, test-guided personalized therapies are more cost-effective than non-test-guided personalized therapies. Hence, a prior test before drug administration seems to be useful for therapeutic decisions, dosing according to the different genotypes or gene activity, and/or reducing adverse drug reactions. However, the results of the studies are mainly influenced, e.g., by sensitivity and specificity of the test procedures, prevalence of biomarkers, and the perspective of the study. Generally, analyses of the CE are an essential part of the reimbursement recommendations. However, to guarantee a comparability of CE of stratified drug therapies, national and international standards for evaluations studies should be defined. 
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